BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9529672)

  • 21. Thoracic FDG PET: state of the art.
    Erasmus JJ; McAdams HP; Patz EF; Goodman PC; Coleman RE
    Radiographics; 1998; 18(1):5-20. PubMed ID: 9460106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncological applications of FDG PET imaging.
    Delbeke D
    J Nucl Med; 1999 Oct; 40(10):1706-15. PubMed ID: 10520713
    [No Abstract]   [Full Text] [Related]  

  • 24. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Present status of PET images: clinical FDG PET in oncology].
    Inoue T
    Nihon Igaku Hoshasen Gakkai Zasshi; 1999 Nov; 59(13):737-44. PubMed ID: 10614103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Diagnosis of colorectal cancer with FDG-PET].
    Uno K
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():168-72. PubMed ID: 14574875
    [No Abstract]   [Full Text] [Related]  

  • 27. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer.
    Imdahl A; Nitzsche E; Krautmann F; Högerle S; Boos S; Einert A; Sontheimer J; Farthmann EH
    Br J Surg; 1999 Feb; 86(2):194-9. PubMed ID: 10100786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Staging recurrent metastatic colorectal carcinoma with PET.
    Delbeke D; Vitola JV; Sandler MP; Arildsen RC; Powers TA; Wright JK; Chapman WC; Pinson CW
    J Nucl Med; 1997 Aug; 38(8):1196-201. PubMed ID: 9255148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
    Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M
    Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
    Feine U; Lietzenmayer R; Hanke JP; Held J; Wöhrle H; Müller-Schauenburg W
    J Nucl Med; 1996 Sep; 37(9):1468-72. PubMed ID: 8790195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [18F-fluorodeoxyglucose positron emission tomography in colorectal cancer: value in primary staging and follow-up].
    Jörg L; Heinisch M; Rechberger E; Kurz F; Klug R; Aufschnaiter M; Hammer J; Langsteger W
    Acta Med Austriaca; 2002; 29(5):176-9. PubMed ID: 12506769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [18FDG PET in the management of malignant lymphoma].
    Cui RX; Zhou Q
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Dec; 25(6):645-9. PubMed ID: 14714303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
    Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
    J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma.
    Delbeke D
    J Nucl Med; 1999 Apr; 40(4):591-603. PubMed ID: 10210218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Fluorodeoxyglucose positron emission tomography (FDG-PET) in the differential diagnosis of pancreatic lesions].
    Zimny M; Schumpelick V
    Chirurg; 2001 Sep; 72(9):989-94. PubMed ID: 11594284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical applications of positron emission tomography in sarcoma management.
    Quak E; van de Luijtgaarden AC; de Geus-Oei LF; van der Graaf WT; Oyen WJ
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):195-204. PubMed ID: 21342039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical applications of FDG-PET in oncology.
    Czernin J
    Acta Med Austriaca; 2002; 29(5):162-70. PubMed ID: 12506767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [18FDG-PET imaging of pancreatic adenocarcinoma].
    Daenen F; Hustinx R; Belhocine T; Focan C; Honoré P; Rigo P
    Rev Med Liege; 2000 Feb; 55(2):89-94. PubMed ID: 10769575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [PET-CT in thoracic disease].
    Laffon E; de Clermont H; Bordenave L
    Rev Mal Respir; 2010 Dec; 27(10):1275-80. PubMed ID: 21163403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can dual-headed 18F-FDG SPET imaging reliably supersede PET in clinical oncology? A comparative study in lung and gastrointestinal tract cancer.
    Lonneux M; Delval D; Bausart R; Moens R; Willockx R; Van Mael P; Declerck P; Jamar F; Zreik H; Pauwels S
    Nucl Med Commun; 1998 Nov; 19(11):1047-54. PubMed ID: 9861621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.